Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
482
Completed, industry sponsors, Psychiatry, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed482
482 trials
Showing 1 to 25, recently updated first.
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy SubjectsPivotal-lookingCompleted
Corium Innovations, Inc.Industry
NCT07452692 · 232 participants · Start Aug 23, 2026 · Primary completion Sep 26, 2026
Drug: Selegiline Transdermal Delivery System · For: Major Depressive Disorder (MDD)
Sites: Elin Pelin, Bulgaria; Sofia, Bulgaria · 3 sites in all
Enalare Therapeutics Inc.Industry
NCT06967259 · 62 participants · Start May 14, 2025 · Primary completion Aug 12, 2026
Drug: ENA-001; Placebo Comparator · For: Respiratory Depression
Sites: Miami, Florida; Overland Park, Kansas
GlaxoSmithKlineGSK (GSK)
NCT06065735 · 38 participants · Start Oct 2, 2023 · Primary completion Jan 8, 2024
Drug: Paroxetine · For: Anxiety Disorders
Sites: London, United Kingdom
Boehringer IngelheimBoehringer Ingelheim
NCT04937829 · 59 participants · Start Jul 20, 2021 · Primary completion Nov 16, 2023
Drug: 5 mg BI 1569912; 20 mg BI 1569912 and 1 more · For: Depressive Disorder, Major
Sites: Garden Grove, California; Torrance, California; Miami, Florida · 10 sites in all
- Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaPivotal-lookingCompleted
BioXcel Therapeutics IncIndustry
NCT04010305 · 135 participants · Start May 22, 2019 · Primary completion Jul 31, 2019
Drug: Sublingual film containing BXCL501 (Dexmedetomidine); Placebo film · For: Agitation; Schizophrenia
Sites: Little Rock, Arkansas; Cerritos, California; Lemon Grove, California · 12 sites in all
- Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid WithdrawalPivotal-lookingCompleted
BioXcel Therapeutics IncIndustry
NCT04470050 · 225 participants · Start Jun 9, 2020 · Primary completion Feb 18, 2021
Drug: Dexmedetomidine; Placebo · For: Opioid Withdrawal
Sites: Miami Lakes, Florida; Marlton, New Jersey; New York, New York
Boehringer IngelheimBoehringer Ingelheim
NCT07001475 · 78 participants · Start Aug 12, 2025 · Primary completion Aug 6, 2026
Drug: BI 3031185; Placebo · For: Borderline Personality Disorder; Attention Deficit Hyperactivity Disorder
Sites: Berlin, Germany; Bonn, Germany; Frankfurt am Main, Germany · 7 sites in all
Intra-Cellular Therapies, Inc.Industry
NCT06627413 · 52 participants · Start Aug 23, 2024 · Primary completion Nov 20, 2025
Drug: Lumateperone Capsule; Lumateperone LAI and 4 more · For: Schizophrenia or Schizoaffective
Sites: Los Alamitos, California; Atlanta, Georgia; Marlton, New Jersey · 4 sites in all
Diamond Therapeutics Inc.Industry
NCT07710027 · 56 participants · Start Oct 19, 2021 · Primary completion Mar 12, 2022
Drug: Psilocybin (low dose) or Placebo · For: Healthy Controls
Sites: Toronto, Canada
Humanis Saglık Anonim SirketiIndustry
NCT07691190 · 32 participants · Start Mar 5, 2026 · Primary completion Jun 2, 2026
Drug: Cariprazine Hard Capsules; Reagila® Hartkapseln (Hard Capsules) (Cariprazine) · For: SCHIZOPHRENIA 1 (Disorder)
Sites: Gujrāt, India
- Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With SchizophreniaCompleted
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT06253546 · 24 participants · Start Mar 28, 2024 · Primary completion Jun 12, 2025
Drug: TV-44749 318mg; Oral Olanzapine 10mg/day and 4 more · For: Schizophrenia
Sites: Beijing, China; Guangzhou, China; Shanghai, China · 6 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00102479 · 21 participants · Start Jul 1, 2004 · Primary completion Jul 1, 2005
Drug: Aripiprazole · For: Schizophrenia; Mania
Sirtsei Pharmaceuticals, Inc.Industry
NCT06570369 · 26 participants · Start Aug 22, 2024 · Primary completion May 11, 2026
Drug: SP-624; Placebo · For: Major Depressive Disorder; Depression; Healthy
Sites: Garden Grove, California; Lincoln, Nebraska
TakedaTakeda (TAK)
NCT01879722 · 77 participants · Start Jun 2013 · Primary completion Jun 2014
Drug: TAK-063; TAK-063 Placebo · For: Schizophrenia
Sites: Glendale, California
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07314333 · 40 participants · Start Feb 5, 2026 · Primary completion Mar 30, 2026
Drug: Centanafadine; Methylphenidate and 1 more · For: ADHD
Sites: Salt Lake City, Utah
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02181803 · 55 participants · Start Aug 5, 2014 · Primary completion Apr 23, 2015
Drug: Elpipodect; Placebo and 1 more · For: Schizophrenia
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05406440 · 53 participants · Start Jul 12, 2022 · Primary completion Feb 24, 2023
Drug: Elpipodect; Placebo · For: Schizophrenia
Sites: Garden Grove, California; Glendale, California; Marlton, New Jersey
- A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05893862 · 107 participants · Start Jun 26, 2023 · Primary completion Feb 22, 2024
Drug: Elpipodect; Moxifloxacin and 1 more · For: Schizophrenia
Sites: Glendale, California; Orange, California; Hallandale, Florida · 4 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04506905 · 63 participants · Start Aug 28, 2020 · Primary completion Mar 22, 2022
Drug: Elpipodect; Placebo · For: Schizophrenia
Sites: Rogers, Arkansas; Glendale, California; Long Beach, California · 6 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02411695 · 43 participants · Start Mar 2015 · Primary completion Jan 1, 2017
Drug: Brexpiprazole (OPC-34712) · For: Schizophrenia
Sites: Little Rock, Arkansas; Culver City, California; Orange, California · 10 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07549581 · 43 participants · Start Nov 7, 2024 · Primary completion Sep 12, 2025
Drug: SEP-380135; Placebo · For: Schizophrenia; Major Depressive Disorder (MDD); Bipolar Disorder
Sites: Los Alamitos, California
Transcend TherapeuticsIndustry
NCT05741710 · 79 participants · Start Mar 1, 2023 · Primary completion Feb 19, 2025
Drug: Methylone; Placebo · For: Post Traumatic Stress Disorder
Sites: Denver, Colorado; Jacksonville, Florida; Maitland, Florida · 16 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02144415 · 80 participants · Start May 1, 2014 · Primary completion Jul 1, 2014
Drug: EB-1020 400 mg; EB-1020 800 mg and 3 more · For: Healthy Volunteers; Drug Users
Sites: Overland Park, Kansas
- Zelquistinel in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Syndeio Biosciences, IncIndustry
NCT03726658 · 226 participants · Start Nov 8, 2018 · Primary completion Oct 23, 2019
Drug: AGN-241751; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Garden Grove, California; Atlanta, Georgia · 5 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07486895 · 44 participants · Start Mar 8, 2023 · Primary completion May 18, 2023
Drug: Centanafadine · For: Healthy Adult Participants
Sites: Lenexa, Kansas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.